Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.54 |
| ▸ | CKS1B | P61024 | 1/20 | 0.53 |
| ▸ | SKP1 | P63208 | 1/20 | 0.53 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL649039 | 0.89 | CKS1B (0.65) | DRD2GPR119CKS1BSKP1SKP2 | |
| SCHEMBL3865823 | 0.83 | KDM1A (0.52) | DRD2GPR119CKS1BSKP1SKP2 | |
| SCHEMBL239933 | 0.83 | GPR119 (0.63) | GPR119CKS1BSKP1SKP2ALDH1A1 | |
| SCHEMBL18901560 | 0.82 | GPR119 (0.54) | DRD2GPR119CKS1BSKP1SKP2 | |
| SCHEMBL1401967 | 0.82 | GPR119 (0.58) | GPR119CKS1BSKP1SKP2 | |
| SCHEMBL1401964 | 0.82 | GPR119 (0.58) | GPR119CKS1BSKP1SKP2 | |
| SCHEMBL30599874 | 0.82 | PDE10A (0.57) | GPR119CKS1BSKP1SKP2 | |
| SCHEMBL21227871 | 0.82 | PDE10A (0.57) | GPR119CKS1BSKP1SKP2 | |
| SCHEMBL8172030 | 0.80 | DRD2 (0.80) | DRD2CKS1BSKP1SKP2ALDH1A1 | |
| SCHEMBL8172032 | 0.80 | DRD2 (0.80) | DRD2CKS1BSKP1SKP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482348-B2 | Piperazinyl substituted cyclohexane-1,4-diamines | JANSSEN PHARMACEUTICA N.V. (BG) | 2009-01-27 | — | — | US | disclosed |
| EP-1871373-A1 | PIPERAZINYL SUBSTITUTED CYCLOHEXANE 1,4-DIAMINES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-02 | — | — | EP | disclosed |
| US-20060223825-A1 | Piperazinyl substituted cyclohexane-1,4-diamines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-10-05 | — | — | US | disclosed |
| WO-2006104686-A1 | PIPERAZINYL SUBSTITUTED CYCLOHEXANE 1,4-DIAMINES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223825-A1 | Piperazinyl substituted cyclohexane-1,4-diamines | ADRA1D, ADRA1A, ADRB1 | DRD2 150/4885GPR119 451/4885CKS1B 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.